FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2212546380> ?p ?o ?g. }

• W2212546380 endingPage "34299" @default.
• W2212546380 startingPage "34288" @default.
• W2212546380 abstract "// Sandra Schmitz 1,2 , Gabriela Bindea 3,4,5 , Roxana Irina Albu 1 , Bernhard Mlecnik 3,4,5 and Jean-Pascal Machiels 1,2 1 Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Brussels, Belgium 2 Department of Head and Neck Surgery, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium 3 INSERM UMRS1138, Laboratory of Integrative Cancer Immunology, Paris, France 4 Université Paris Descartes, Rue de l’Ecole de Médecine, Paris, France 5 Cordeliers Research Centre, Université Pierre et Marie Curie Paris, Paris, France Correspondence to: Jean-Pascal Machiels, email: // Keywords : head and neck cancer, epithelial-mesenchymal transition, cancer-associated fibroblasts, anti-EGFR therapy, pharmacodynamic Received : September 02, 2015 Accepted : September 09, 2015 Published : September 30, 2015 Abstract Purpose: To investigate if cetuximab induces epithelial to mesenchymal transition (EMT) and activation of cancer associated fibroblast (CAF) in the tumors of patients with squamous cell carcinoma of the head and neck (SCCHN). Methods: Cetuximab was administered for two weeks prior to surgery to 20 treatment-naïve patients. Five untreated patients were included as controls. Tumor biopsies were performed at baseline and before surgery. Gene expression profiles and quantitative real-time PCR (qRT-PCR) analysis of the pre-and post-treatment biopsies were compared. To further investigate EMT and CAF, correlations between previously described EMT and CAF markers and our microarray data set were calculated. Results : Gene expression profile analyses and qRT-PCR showed that some of the genes modified by cetuximab were related to CAFs and EMT ( ZNF521 , CXCL12, ASPN, OLFML3, OLFM1, TWIST1, LEF1, ZEB1, FAP). We identified 2 patient clusters with different EMT and CAF characteristics. Whereas one cluster showed clear upregulation of expression of genes implicated in CAF and EMT including markers of embryologic pathways like NOTCH and Wnt, the other did not. Conclusion: Even if EMT and CAFs are implicated in cetuximab resistance in pre-clinical models, we demonstrate for the first time that these molecular processes may occur clinically early on." @default.
• W2212546380 created "2016-06-24" @default.
• W2212546380 creator A5028429315 @default.
• W2212546380 creator A5062069569 @default.
• W2212546380 creator A5065592180 @default.
• W2212546380 creator A5066800365 @default.
• W2212546380 creator A5078219830 @default.
• W2212546380 date "2015-09-30" @default.
• W2212546380 modified "2023-10-01" @default.
• W2212546380 title "Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer" @default.
• W2212546380 cites W1856327990 @default.
• W2212546380 cites W1926371918 @default.
• W2212546380 cites W1963577649 @default.
• W2212546380 cites W1964588690 @default.
• W2212546380 cites W1971402898 @default.
• W2212546380 cites W1980534733 @default.
• W2212546380 cites W1993507992 @default.
• W2212546380 cites W2005204942 @default.
• W2212546380 cites W2023906705 @default.
• W2212546380 cites W2031694054 @default.
• W2212546380 cites W2035247707 @default.
• W2212546380 cites W2043669256 @default.
• W2212546380 cites W2068277926 @default.
• W2212546380 cites W2069482953 @default.
• W2212546380 cites W2075077128 @default.
• W2212546380 cites W2076419931 @default.
• W2212546380 cites W2080261745 @default.
• W2212546380 cites W2083106832 @default.
• W2212546380 cites W2086468784 @default.
• W2212546380 cites W2088193529 @default.
• W2212546380 cites W2089663915 @default.
• W2212546380 cites W2092660010 @default.
• W2212546380 cites W2110088809 @default.
• W2212546380 cites W2111927373 @default.
• W2212546380 cites W2112845420 @default.
• W2212546380 cites W2113472355 @default.
• W2212546380 cites W2124570984 @default.
• W2212546380 cites W2129034213 @default.
• W2212546380 cites W2139624241 @default.
• W2212546380 cites W2140747142 @default.
• W2212546380 cites W2144020201 @default.
• W2212546380 cites W2145478177 @default.
• W2212546380 cites W2148806906 @default.
• W2212546380 cites W2149447281 @default.
• W2212546380 cites W2150057850 @default.
• W2212546380 cites W2150964566 @default.
• W2212546380 cites W2151839266 @default.
• W2212546380 cites W2152026276 @default.
• W2212546380 cites W2155311724 @default.
• W2212546380 cites W2155384808 @default.
• W2212546380 cites W2157792708 @default.
• W2212546380 cites W2161033773 @default.
• W2212546380 cites W2163342203 @default.
• W2212546380 cites W2165303797 @default.
• W2212546380 cites W2166106808 @default.
• W2212546380 cites W2169268148 @default.
• W2212546380 cites W2169589032 @default.
• W2212546380 doi "https://doi.org/10.18632/oncotarget.5924" @default.
• W2212546380 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4741452" @default.
• W2212546380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26437222" @default.
• W2212546380 hasPublicationYear "2015" @default.
• W2212546380 type Work @default.
• W2212546380 sameAs 2212546380 @default.
• W2212546380 citedByCount "48" @default.
• W2212546380 countsByYear W22125463802016 @default.
• W2212546380 countsByYear W22125463802017 @default.
• W2212546380 countsByYear W22125463802018 @default.
• W2212546380 countsByYear W22125463802019 @default.
• W2212546380 countsByYear W22125463802020 @default.
• W2212546380 countsByYear W22125463802021 @default.
• W2212546380 countsByYear W22125463802022 @default.
• W2212546380 countsByYear W22125463802023 @default.
• W2212546380 crossrefType "journal-article" @default.
• W2212546380 hasAuthorship W2212546380A5028429315 @default.
• W2212546380 hasAuthorship W2212546380A5062069569 @default.
• W2212546380 hasAuthorship W2212546380A5065592180 @default.
• W2212546380 hasAuthorship W2212546380A5066800365 @default.
• W2212546380 hasAuthorship W2212546380A5078219830 @default.
• W2212546380 hasBestOaLocation W22125463801 @default.
• W2212546380 hasConcept C121608353 @default.
• W2212546380 hasConcept C126322002 @default.
• W2212546380 hasConcept C137620995 @default.
• W2212546380 hasConcept C143998085 @default.
• W2212546380 hasConcept C185592680 @default.
• W2212546380 hasConcept C2776530083 @default.
• W2212546380 hasConcept C2776833033 @default.
• W2212546380 hasConcept C2779013556 @default.
• W2212546380 hasConcept C2779998722 @default.
• W2212546380 hasConcept C502942594 @default.
• W2212546380 hasConcept C526805850 @default.
• W2212546380 hasConcept C55493867 @default.
• W2212546380 hasConcept C62478195 @default.
• W2212546380 hasConcept C71924100 @default.
• W2212546380 hasConcept C76419328 @default.
• W2212546380 hasConceptScore W2212546380C121608353 @default.
• W2212546380 hasConceptScore W2212546380C126322002 @default.
• W2212546380 hasConceptScore W2212546380C137620995 @default.
• W2212546380 hasConceptScore W2212546380C143998085 @default.

• next